Marina Chiara Garassino to Pyrimidines
This is a "connection" page, showing publications Marina Chiara Garassino has written about Pyrimidines.
Connection Strength
0.700
-
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
Score: 0.172
-
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
Score: 0.152
-
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948.
Score: 0.129
-
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer Res. 2010 Oct; 30(10):4289-95.
Score: 0.078
-
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Rep Med. 2023 11 21; 4(11):101280.
Score: 0.048
-
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer. 2021 10; 160:152-165.
Score: 0.041
-
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 09; 32(9):1101-1110.
Score: 0.041
-
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 07; 157:9-16.
Score: 0.041